Reported research findings
- No established human clinical trials define efficacy or safety for this analog in people to date; reported effects come from mechanism and research-community use.
MUSCLE, GROWTH & RECOVERY
IGF-1 LR3
A long-acting form of IGF-1, the muscle-building signal that growth hormone works through.
IGF-1 LR3 is a long-acting form of natural IGF-1, the signal growth hormone acts through and a powerful driver of muscle repair and growth. The modification keeps more of it active in circulation for longer. It is widely used in performance research, though its evidence base rests on mechanism and real-world use rather than human clinical trials.
Why BLP features IGF-1 LR3
Included as a mechanistically powerful compound with an established performance-research following. Human clinical trial evidence is minimal, so despite widespread use it is presented as experimental—popularity does not substitute for documented human trials.
Mechanism
Binds IGF-1 receptors, activating the satellite cells that repair muscle, raising protein synthesis, and promoting hyperplasia—the formation of new muscle fibers.
The LR3 modification stops it from being captured by the carrier proteins that normally hold IGF-1 inactive, so substantially more of it stays available.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- Reported rapid lean-muscle gains and improved muscle fullness in research use.
- Reported enhanced recovery and reduced soreness; localized growth when injected into specific muscles.
- Dose-dependent effects noted, with possible hypoglycemia, water retention, or joint discomfort; researchers typically start low to assess tolerance.
Regulatory status
IGF-1 LR3 is investigational with minimal human clinical evidence. Sold and offered strictly for laboratory and research use.